In conclusion, CNP520 is unique among BACE1 inhibitors, particularly for its selectivity for BACE1 over BACE2 and its safety profile, making it a compelling candidate drug for long‐term use for the prevention of AD in presymptomatic individuals. This evidence concerns the gene BACE2 and Alzheimer disease.